LEAWOOD, Kan., Jan. 18, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, today announced GALLIPRANT® (grapiprant tablets) was named Animal Pharm's Best Companion Animal Product for 2017.
Galliprant was made commercially available to veterinarians in January 2017 through a license and collaboration agreement with Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY). Galliprant provides targeted pain control from the earliest diagnosed stages of canine osteoarthritis and is the first piprant (a prostaglandin receptor antagonist) approved for use in veterinary medicine. It represents the evolution of canine anti-inflammatory drugs by specifically blocking the prostaglandin EP4 receptor, which is the primary mediator of OA pain and inflammation.1
This is the fourth consecutive year Aratana has been honored with an award from Animal Pharm. Aratana was named Best Company in North America 2016 based on the FDA approval of three innovative therapeutics, GALLIPRANT® (grapiprant tablets), ENTYCE® (capromorelin oral solution) and NOCITA® (bupivacaine liposome injectable suspension), as well as its evolution to a commercial company.
Indication
Galliprant is indicated for the control of pain and inflammation associated with osteoarthritis in dogs.
Important Safety Information
Not for use in humans. For use in dogs only. Keep this and all medications out of reach of children and pets. Store out of reach of dogs and other pets in a secured location in order to prevent accidental ingestion or overdose. Do not use in dogs that have a hypersensitivity to grapiprant. If Galliprant is used long term, appropriate monitoring is recommended. Concomitant use of Galliprant with other anti-inflammatory drugs, such as COX-inhibiting NSAIDs or corticosteroids, should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs. (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. The most common adverse reactions were vomiting, diarrhea, decreased appetite, and lethargy. For full prescribing information call 1-888-545-5973.
About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to dogs and cats in a capital and time efficient manner. The company's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.
Contacts
For investor inquires:
Craig Tooman
ctooman@aratana.com
(913) 353-1026
For media inquiries:
Rachel Reiff
rreiff@aratana.com
(913) 353-1050
References
- Kirkby Shaw, K., Rausch-Derra, L., and Rhodes, L. 2016. "Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation." Vet. Med. Sci. 2:3-9.
SOURCE Aratana Therapeutics